Sign In
Buy REGN
$628.73
+9.78 (+1.58%)
At Close: Jun 04, 2026
NEW YORK CITY, NY / ACCESS Newswire / February 19, 2025 / Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Re
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
SAN DIEGO, Feb. 18, 2025 (GLOBE NEWSWIRE) -- Robbins LLP reminds investors that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Regeneron Pharmaceu
INVESTOR ALERT: Pomerantz Law Firm Announces the Filing of a Class Action Against Regeneron Pharmaceuticals, Inc. - REGN
06:21pm, Tuesday, 18'th Feb 2025
NEW YORK , Feb. 18, 2025 /PRNewswire/ -- Pomerantz LLP announces that a class action lawsuit has been filed against Regeneron Pharmaceuticals, Inc. ("Regeneron" or the "Company") (NASDAQ: REGN). S
March 10, 2025 Deadline: Contact Levi & Korsinsky to Join Class Action Suit Against REGN
03:30pm, Tuesday, 18'th Feb 2025
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
Regeneron Pharmaceuticals (REGN) Faces Mounting Pressure on Sales, Legal Fronts - Hagens Berman
12:45pm, Tuesday, 18'th Feb 2025
SAN FRANCISCO, CA / ACCESS Newswire / February 18, 2025 / Regeneron Pharmaceuticals Inc. (NASDAQ:REGN) is facing headwinds on multiple fronts, including disappointing sales figures, ongoing legal chal
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
Regeneron Pharmaceuticals, Inc. (REGN) Investors Who Lost Money Have Opportunity to Lead Securities Fraud Lawsuit
12:00pm, Tuesday, 18'th Feb 2025
BENSALEM, Pa. , Feb. 18, 2025 /PRNewswire/ -- The Law Offices of Howard G.
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
The Schall Law Firm Invites Investors With Losses To Join A Securities Fraud Case Against Regeneron Pharmaceuticals, Inc.
11:00am, Tuesday, 18'th Feb 2025
LOS ANGELES, CA / ACCESS Newswire / February 18, 2025 / The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Regeneron Pharmaceutical
This Company Just Initiated a Quarterly Dividend: Time to Buy?
09:45am, Tuesday, 18'th Feb 2025
Biotech giant Renegeron Pharmaceuticals (REGN -0.10%) reported its fourth-quarter and full-year 2024 earnings on Feb. 4. The company's results were strong, coming in ahead of analyst estimates.
SNY and REGN's Dupixent sBLA for Skin Disease Gets FDA's Priority Tag
08:41am, Tuesday, 18'th Feb 2025
The FDA is set to give its decision on SNY and REGN's sBLA for Dupixent for bullous pemphigoid by June 20, 2025.
NEW YORK, NY / ACCESS Newswire / February 18, 2025 / If you suffered a loss on your Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) investment and want to learn about a potential recovery under the fede
